Why the study?
Despite successful TAVR for severe aortic stenosis, patients remain at high risk for heart failure hospitalization and death.
Population
Patients undergoing TAVR for severe aortic stenosis
Comparison
SGLT2 inhibitors vs control post-TAVR
Design
Systematic review and meta-analysis of real-world evidence and the DAPA-TAVI randomized trial
Despite successful transcatheter aortic valve replacement (TAVR) for severe aortic stenosis, patients remain at high risk for heart failure (HF) hospitalization and death. This systematic review and meta-analysis of real-world evidence and the DAPA-TAVI randomized trial evaluated the efficacy and safety of SGLT2 inhibitors (SGLT2i) following TAVR.
No takes yet. Share an insight, caveat, or question.
Mohammed et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: